comparemela.com

Latest Breaking News On - Ann rheum - Page 4 : comparemela.com

The New England Journal of Medicine Publishes Second

Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with.

United statesUnited kingdomCharles weissmannWalter gilbertHeinz schallerNathalie franchimontRichard furieAshleigh kossBarry rubensteinMike henckeKenneth murrayCenters for diseasePrevention national lupus registriesBiogen incImmunology development unit at biogenExchange commission

Kyverna Therapeutics Names Georg Schett, M D , and Peter A Merkel, M D , MPH, to Scientific Advisory Board

/PRNewswire/ Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced.

Harvard universityUnited statesPetera merkelDominic borieGeorg schettYale universityHospital harvard medical schoolCollaborative research centreHead of the department internal medicineFriedrich alexander universityUniversity of innsbruckGerman research foundationHospital of the university pennsylvaniaScleroderma clinical trials consortiumUniversity of pennsylvaniaNational academy of sciences germany

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

/PRNewswire/ UCB, a global pharmaceutical company, today announced new 24-week data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, evaluating.

United statesUnited kingdomBruxelles capitaleEmmanuel caeymaexMusculoskelet disordEimear obrienAntje witteJ clin pharmacolImmunology solutionsEuropean congressBrand communicationsUcb incDrug administrationAssessment of spondyloarthritis international societyCorporate communicationsSource ucb inc

Nordic Pharma Inc : NORDIC PHARMA Files Submission to Health Canada for the Marketing Authorization of Methotrexate Autoinjector for Treating Rheumatoid Arthritis in Canada

NORDIC PHARMA, a SEVER Life Sciences company, announced today the submission of a New Drug Submission to Health Canada for its methotrexate auto-injector, Nordimetfor the treatment of severe disabling

United statesUnited kingdomKostenloser wertpapierhandelArthritis research united kingdomNordic pharma incLife sciencesDrug submission to health canadaNew drug submissionHealth canadaPharma americasNordic pharmaGlobal burdenAnn rheumArthritis research unitedRheum disChronic disease surveillance system

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Saphnelo approved in EU for SLE

Investegate announcements from AstraZeneca PLC, Saphnelo approved in EU for SLE

United kingdomUnited statesNoord hollandRonald van vollenhovenAstrazeneca saphneloAl sawahAdrian kempCenters for diseaseMedarex incEuropean commissionAmerican college of rheumatologyCompany on twitter astrazenecaAmsterdam rheumatology centerInvestor relations teamEuropean unionLupus foundation of america

vimarsana © 2020. All Rights Reserved.